Guardant Health
About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Employees: 1,779
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
29% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 73
4.83% more ownership
Funds ownership: 97.81% [Q2] → 102.63% (+4.83%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
6% less funds holding
Funds holding: 280 [Q2] → 264 (-16) [Q3]
16% less capital invested
Capital invested by funds: $3.38B [Q2] → $2.83B (-$545M) [Q3]
27% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 59
62% less call options, than puts
Call options by funds: $21.3M | Put options by funds: $56M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
11%
upside
Avg. target
$43
35%
upside
High target
$50
58%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Julia Qin 80% 1-year accuracy 4 / 5 met price target | 58%upside $50 | Overweight Maintained | 7 Nov 2024 |
Goldman Sachs Matthew Sykes 64% 1-year accuracy 29 / 45 met price target | 14%upside $36 | Buy Maintained | 7 Nov 2024 |
Bernstein Eve Burstein 67% 1-year accuracy 4 / 6 met price target | 11%upside $35 | Outperform Maintained | 30 Oct 2024 |
Leerink Partners | 58%upside $50 | Outperform Maintained | 17 Oct 2024 |
Financial journalist opinion
Based on 6 articles about GH published over the past 30 days
Neutral
Business Wire
1 day ago
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
PALO ALTO, Calif. & TAMPA, Fla.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. Recognizing the evolving landscape of precision medicine, the collaboration combines MiBA's cutting-.
Neutral
Business Wire
2 days ago
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
NEW YORK--(BUSINESS WIRE)--COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA's research-grade electronic health record (EHR) data from academic and community care centers and Guardant's clinicogenomic testing data to accelerate the development of new cancer therapies. Using the extensiv.
Neutral
Business Wire
3 days ago
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC). As p.
Neutral
Business Wire
1 week ago
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating the benefits of its precision oncology tests, real-world clinical-genomic database and AI analytics in optimizing therapy selection, identifying resistance mutations, and predicting long-term outcomes at the San Antonio Breast Cancer Symposium (SABCS) 2024 in San Antonio, Texas, Dec. 10-13, 2024.
Positive
Forbes
2 weeks ago
Guardant Health Stock Flashing Surefire ‘Buy' Signal
Biotechnology stock Guardant Health (GH) is trading at 15-month highs today, last seen up 7% at $38.28. Shares have added 107.7% over the last nine months, and now stand nearly 42% higher in 2024.
Neutral
PRNewsWire
3 weeks ago
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera Found to Have Willfully Misled Oncologists in an Effort to Thwart Competition PALO ALTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company, today announced that a jury in the U.S. District Court for the Northern District of California (the "Court") unanimously found in favor of Guardant Health on all of its claims from its May 2021 lawsuit against Natera, Inc. (Nasdaq: NTRA) ("Natera") for false advertising and unfair competition.
Neutral
Business Wire
1 month ago
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 50,349 shares of its common stock to three new non-executive employees with a gra.
Positive
The Motley Fool
1 month ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The rock star money manager is starting to roll with the rallying market.
Positive
Investors Business Daily
1 month ago
Guardant Health Rockets 25% On An 'Impressive' Beat Following Exact Sciences' Flop
Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield. The post Guardant Health Rockets 25% On An 'Impressive' Beat Following Exact Sciences' Flop appeared first on Investor's Business Daily.
Neutral
Seeking Alpha
1 month ago
Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript
Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™